Onconova (NASDAQ:ONTX) Stocks Soar 75%. A Penny Stock To Buy?

May 19, 2021 09:05 PM NZST | By Raza Naqvi
 Onconova (NASDAQ:ONTX) Stocks Soar 75%. A Penny Stock To Buy?
Image source: Yuriy K, Shutterstock

Summary

  • Stocks of Onconova Therapeutics Inc (NASDAQ:ONTX, ONTX:US) skyrocketed by 75 per cent to close at US$ 1.08 on Tuesday, May 18.
  • ONTX stocks have been recording quite a rally on the equity market, swelling 107 per cent in the past week.
  • A clinical-stage biopharmaceutical firm, Onconova focuses on developing drugs for people suffering from cancer.

Stocks of Onconova Therapeutics Inc (NASDAQ:ONTX, ONTX:US) skyrocketed by 75 per cent to close at US$ 1.08 on Tuesday, May 18. ONTX stocks have been recording quite a rally on the equity market, swelling 107 per cent in the past week.

A clinical-stage biopharmaceutical firm, Onconova focuses on developing drugs for people suffering from cancer. It recently developed a drug named Rigosertib to treat cases of chronic leukaemia.

In April, the company announced that a patient was administered Rigosertib to assess its efficacy on a patient with skin disorder RDEB (recessive dystrophic epidermolysis bullosa).

Let’s take a look at Onconova Therapeutics’ stocks and financial performance.

Onconova Therapeutics Inc (NASDAQ:ONTX, ONTX:US)

In the past year, Onconova stock recorded a significant growth of 190 per cent, beating the S&P 500-Pharmaceuticals (Sub Industry) sector. Its six-month stock price growth sits at 314 per cent.

As of Tuesday’s close, at US$ 1.08, the stock was 44 per cent down from its 52-week high of US$ 1.93 (February 18, 2021). Investors looking to invest in this stock might use this discounted price as an entry point.

Copyright © 2021 Kalkine Media

In Q1 FY21, the company recorded cash and cash equivalents of US$ 48 million. It also had net proceeds of US$ 35.2 million generated from two equity offerings.

Key Initiatives of Onconova Therapeutics Inc

While announcing its first quarter report for fiscal 2021, Onconova Therapeutics said that it is conducting Phase 1 trials of a solid tumour treatment in China. The company is studying the effects of ‘ON 123300’, a multi-kinase inhibitor that can reportedly reduce tumour growth.

Onconova Managing Director Steven M Fruchtman said that the third cohort of the Phase 1 study is expected to begin soon in China. He added that ON 123300 appears to be suiting the patients and no toxicities have been observed to date.

Meanwhile, the 'ON 123300 Phase 1' trial is open for enrolment in the US, and the biopharma company is actively looking for patients for the study.

The above constitutes a preliminary view and any interest in stocks should be evaluated further from an investment point of view.


Disclaimer

The content on this website, including, but not limited to, any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (“Content”) is a service provided by Kalkine Media New Zealand Limited (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide financial advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests users seek financial advice from a financial advice provider, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all liability to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without any express or implied warranties of any kind. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit a source wherever it is indicated or is found to be necessary or desirable.

Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.